Maxim Group Reiterates Buy Rating for Xtant Medical (XTNT)

Xtant Medical (NYSEAMERICAN:XTNT)‘s stock had its “buy” rating reissued by equities research analysts at Maxim Group in a research note issued to investors on Wednesday. They currently have a $10.00 price target on the medical device company’s stock. Maxim Group’s price objective would suggest a potential upside of 110.97% from the stock’s current price.

Shares of Xtant Medical (NYSEAMERICAN XTNT) traded down $0.04 during trading on Wednesday, hitting $4.74. The stock had a trading volume of 13,497 shares, compared to its average volume of 14,093. The firm has a market capitalization of $7.88, a price-to-earnings ratio of -2.91 and a beta of 0.41. Xtant Medical has a twelve month low of $3.96 and a twelve month high of $14.52.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, November 21st. The medical device company reported ($0.47) earnings per share for the quarter. The firm had revenue of $19.79 million during the quarter.

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC boosted its holdings in shares of Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) by 145.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 291,892 shares of the medical device company’s stock after buying an additional 173,100 shares during the period. Renaissance Technologies LLC owned approximately 1.43% of Xtant Medical worth $167,000 as of its most recent filing with the Securities and Exchange Commission.

TRADEMARK VIOLATION NOTICE: This story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

About Xtant Medical

Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.

Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with's FREE daily email newsletter.

Leave a Reply